Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics ; volume:22 ; number:1 ; day:10 ; month:1 ; year:2024 ; pages:1-9 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (10.1.2024), 1-9, 12.2024
- Creator
-
Yolchuyeva, Sevinj
Ebrahimpour, Leyla
Tonneau, Marion
Lamaze, Fabien
Orain, Michele
Coulombe, François
Malo, Julie
Belkaid, Wiam
Routy, Bertrand
Joubert, Philippe
Manem, Venkata SK
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-04854-z
- URN
-
urn:nbn:de:101:1-2024032510550933868591
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yolchuyeva, Sevinj
- Ebrahimpour, Leyla
- Tonneau, Marion
- Lamaze, Fabien
- Orain, Michele
- Coulombe, François
- Malo, Julie
- Belkaid, Wiam
- Routy, Bertrand
- Joubert, Philippe
- Manem, Venkata SK
- SpringerLink (Online service)
Other Objects (12)
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Integration of deep learning and habitat radiomics for predicting the response to immunotherapy in NSCLC patients
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study
Impact of NSCLC metabolic remodeling on immunotherapy effectiveness
Validation of a multiomic model of plasma extracellular vesicle PD-L1 and radiomics for prediction of response to immunotherapy in NSCLC
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line
Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment